A Comprehensive Review of the Therapeutic Potential of Mucuna Pruriens.
Level 5 - mechanism / opinion, no new human data
Narrative review of phytochemical and pharmacological literature without systematic review of clinical trials
PubMed 41828855 · doi:10.3390/molecules31050868
What was done
Authors searched Google Scholar, Scopus, PubMed, and Web of Science databases to compile literature on the chemical composition and therapeutic properties of all plant parts (seeds, leaves, roots, and pods) of *Mucuna pruriens*.
What was found
The abstract reports no quantitative values, metrics, or study counts. It qualitatively notes that *Mucuna pruriens* contains diverse secondary metabolites—including phenolic acids, flavonoids, tannins, saponins, and alkaloids—with high concentrations of L-DOPA in the seeds. Research is primarily focused on seeds and originates predominantly from native habitat regions, leaving non-seed tissues and non-native regions understudied.
Why it matters
This review highlights the distribution of bioactive constituents across *Mucuna pruriens* and underscores the need to expand chemical profiling beyond seed-derived L-DOPA.
Limits
The abstract provides no quantitative data, search protocol details, study counts, or risk of bias assessments. The findings reflect narrative phytochemical compilation rather than human clinical trial synthesis.
Cited by
- supports Mucuna pruriens contains L-DOPA, a biochemical precursor to dopamine.